Abstract
The report that dichlorisoprenaline, DCI, the first introduced beta-adrenergic receptor blocking agent, could block beta-adrenergic receptors initiated a research for other beta-receptor blocking agents.
Thereafter, several compounds, such as pronethalol [Black and Stephenson (I) ], propranolol [Black et al. (2)], H56/28 [Åblad et al. (3)] and others, have been described as capable of producing more potensive and selective blockade of beta-adrenergic receptor sites.
Recently a new beta-adrenergic receptor antagonist, 4-(2-hydroxy-3-isopropylamino-propoxy)-indole (LB-46) (4), has been introduced. This compound is a basic indole with a side-chain characteristic of beta-adrenergic receptor blocking agents.
Investigation was performed to make clear an antagonistic effect of this compound against isoprenaline, adrenaline and noradrenaline in comparison with the above-men-tioned beta-adrenergic receptor blocking agents.
